VRDN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Viridian Therapeutics Inc (VRDN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows promise with upcoming catalysts like the PDUFA decision and potential commercial launch in 2026, the recent pre-market price drop, neutral trading sentiment, and lack of immediate strong signals from Intellectia Proprietary Trading Signals suggest waiting for more clarity on the stock's trajectory. Additionally, the recent large sell-off by Kynam Capital raises concerns about near-term volatility.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 52.005, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 28.042, with resistance at 29.41 and support at 26.674. Pre-market price is down 1.42%, suggesting short-term weakness.
Upcoming PDUFA decision on June 30, 2026, for intravenous veligrotug under priority review.
Potential commercial launch in TED in mid-
Analysts maintain positive ratings with price targets ranging from $42 to $50.
Kynam Capital sold 2,957,386 shares in Q4, signaling a cautious outlook.
Pre-market price drop of 1.42% and neutral trading sentiment from hedge funds and insiders.
High implied volatility (209.43%) and recent stock volatility may deter beginner investors.
In Q4 2025, revenue increased by 83.33% YoY to $132,000, and net income improved by 50.96% YoY to -$120.36 million. EPS also improved by 28.28% YoY to -1.27. Despite these improvements, the company remains unprofitable.
Analysts maintain positive ratings with price targets ranging from $42 to $50. RBC, Jefferies, Evercore ISI, and UBS all highlight upcoming catalysts and potential for strong performance in 2026, but the stock's current setup is more focused on long-term growth rather than immediate gains.
